BOULDER, Colo.--(BUSINESS WIRE)--Feb. 9, 2012--
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its President
and Chief Scientific Officer, Kevin Koch, will speak at the Leerink
Swann Healthcare Conference in New York. The public is welcome to
participate in the conference through a webcast on the Array BioPharma
website.
|
Event:
|
|
|
|
|
Leerink Swann Healthcare Conference
|
|
Presenter:
|
|
|
|
|
Kevin Koch, Ph.D., President and Chief Scientific Officer
|
|
Date:
|
|
|
|
|
Wednesday, February 15, 2012
|
|
Time:
|
|
|
|
|
8:00 a.m. Eastern Time
|
|
Location:
|
|
|
|
|
The Waldorf Astoria, New York, NY
|
|
Webcast:
|
|
|
|
|
www.arraybiopharma.com
|
|
|
|
|
|
|
|
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more information on
Array, please go to www.arraybiopharma.com.
Source: Array BioPharma
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
View printer-friendly version
